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Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcuta-
neous administration, in patients with chronic coronary syndromes (CCS).
...................................................................................................................................................................................................
Methods
and results
In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcuta-
neous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov:
NCT03384966). Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance
aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU)
<100 at 30 min post-dose and lasting >_3 h. At 30 min post-dose, 89% of patients were responders to selatogrel
8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001). PRU values (mean ± standard deviation)
were 10 ± 25 (8 mg), 4 ± 10 (16 mg), and 163 ± 73 (placebo) at 15 min and remained <100 up to 8 h for both
doses, returning to pre-dose or near pre-dose levels by 24 h post-dose. LTA data showed similarly rapid and
potent inhibition of platelet aggregation. Selatogrel plasma concentrations peaked 30 min post-dose. Selatogrel
was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence
interval: 4–11%).
...................................................................................................................................................................................................
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Conclusions Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent,
and consistent platelet P2Y12 inhibition sustained for >_8 h and reversible within 24 h. Further studies of subcutane-
ous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.
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Introduction
The activation of platelets at sites of vascular injury is a key step in
thrombus formation, mediated in part by adenosine diphosphate
(ADP)-induced activation of platelet P2Y12 receptors.
1 Current
treatment guidelines recommend the use of dual oral antiplatelet
therapy consisting of aspirin and a platelet P2Y12 receptor antagonist
(‘P2Y12 inhibitor’) for the management of patients with acute coron-
ary syndromes (ACS) and/or patients undergoing percutaneous cor-
onary intervention (PCI) in order to prevent stent thrombosis and
future atherothrombotic events.2–5 In the absence of contraindica-
tions, ticagrelor and prasugrel are recommended as the oral P2Y12
inhibitors for most ACS patients in preference to clopidogrel, in view
of their more potent and consistent antiplatelet effects and superior
net clinical benefits.2,3
However, the onset of action of all oral P2Y12 inhibitors may be
delayed by up to 6 h or more in the setting of acute myocardial infarc-
tion (AMI), and the only non-oral P2Y12 inhibitor available is cangre-
lor, which is administered intravenously in patients undergoing PCI
when oral P2Y12 inhibitors are not indicated or not yet administered.
Therefore, there is a need for a P2Y12 inhibitor that achieves
consistently fast and effective platelet inhibition in the acute phase of
a myocardial infarction.6,7
Selatogrel (ACT-246475) is a 2-phenylpyrimidine-4-carboxamide
analogue that represents a novel class of reversibly-binding P2Y12 in-
hibitor, distinct from the two classes represented by ticagrelor and
cangrelor. Selatogrel is being developed for subcutaneous (s.c.)
administration for early, pre-hospital treatment of AMI.8,9 Preclinical
data from a rodent ferric chloride model suggest that selatogrel has
a potentially lower risk of bleeding and Phase 1 data from healthy
subjects indicate selatogrel is well tolerated at doses up to 32 mg,
with a favourable pharmacodynamic (PD) and pharmacokinetic (PK)
profile.9,10
To investigate the PD and PK properties of selatogrel in patients
with atherosclerotic disease, the present study was conducted in
patients with stable chronic coronary syndromes (CCS). Patients
with CCS represent a population that permits more frequent blood
sampling without increasing the risk to patient safety, while avoiding
interference with standard of care required in an emergency setting
such as AMI. Furthermore, assessment in a population of patients
with CCS allows better control and stability of concomitant treat-
ments, and therefore more accurate characterization of the PD and
PK profiles of selatogrel in the presence of background antiplatelet
therapies. The main objective of this study was to characterize the
inhibition of platelet aggregation relative to placebo after a single s.c.
injection of selatogrel in patients with CCS receiving conventional
background oral antiplatelet therapy.
Methods
Study population
Patients with CCS were identified by either (i) history of coronary artery
disease with coronary artery stenosis on angiography >_ 50% or (ii) previ-
ously documented AMI occurring more than 3 months prior to
randomization.
Eligible male and female patients were aged 18–85 years, inclusive, and
females of childbearing potential were required to have a negative urine
pregnancy test both at screening and immediately before randomization.
Patients were required to have a body weight of >_40.0 kg and have had
no changes to their current antiplatelet medication in the prior 1 month.
Patients were excluded if they had conditions associated with increased
bleeding risk or likely to impair study procedures or safety, or if they
were treated with inhibitors of organic anion-transporting polypeptide
(OATP)1B1 or OATP1B3 of which selatogrel is a substrate. Additional
exclusion criteria were ACS, PCI, any intervention for peripheral artery
disease, acute ischaemic stroke, or transient ischaemic attack within
3 months prior to randomization. Detailed inclusion and exclusion crite-
ria are presented in the Supplementary material online.
Study design
This was a prospective, multi-national, double-blind, randomized,
placebo-controlled, parallel-group, Phase-2 study (ClinicalTrials.gov regis-
tration number NCT03384966) of a single s.c. administration of selatog-
rel at two dose levels in CCS patients receiving conventional background
antiplatelet therapy. All study procedures were performed according to
protocols approved by local regulatory authorities and all patients pro-
vided written informed consent prior to any study-mandated procedure.
Eligible patients were randomized to one of eight groups based on
treatment (selatogrel or matching placebo), dose (8 or 16 mg), and s.c. in-
jection site (thigh or abdomen) (Figure 1). The 8 and 16 mg doses of sela-
togrel were selected based on data from the single ascending dose study9
and on modelling to achieve at least 85% inhibition of ADP-induced plate-
let aggregation that was sustained for at least 3 up to 8 h. Patients and
investigators were both blinded to the study treatment (selatogrel or
placebo). Selatogrel and placebo were not distinguishable and were
provided as lyophilizate for reconstitution prior to s.c. administration.
Investigators reconstituted selatogrel/placebo to the same volume for 8
and 16 mg out of sight of the patients and so only patients were blinded
to the dose. Blood samples for PD and PK measurements were collected
pre-dose and then 15 min, 30 min, and 1, 2, 4, 8, and 24 h following the
single dose of s.c. study medication.
The treatment period was defined as lasting 2 days after study medica-
tion administration, representing5 half-lives of selatogrel. Patients were
followed up by telephone call or a visit at 1 month (28–35 days).
Blood samples
Venous blood for PD assessment was collected into Monovette tubes
containing the direct thrombin inhibitor phenylalanine-proline-arginine-
Selatogrel, a subcutaneous P2Y12 receptor antagonists 3133
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chloromethyl ketone (PPACK) as anticoagulant and assessments were
made within 2 h of blood collection. PPACK was used as the anticoagu-
lant since the conventional anticoagulant for platelet function studies,
trisodium citrate dihydrate (‘citrate’), is recognized to affect the
potency of some antiplatelet drugs,11,12 as has been found for selatogrel
(unpublished data on file, Idorsia Pharmaceuticals Ltd). Venous blood for
PK assessment was collected into Monovette tubes containing ethylene-
diaminetetraacetic acid and plasma derived within 30 min of collection
for storage at or below -20C prior to analysis.
Pharmacodynamic assessments
Pharmacodynamic assessments were performed by laboratory staff
who were blinded to both treatment and dose. The investigators
remained blinded to the results for the duration of the study. The
principal measurement of platelet reactivity was the VerifyNow
PRUTest (Accriva Diagnostics, San Diego, CA, USA), assessing plate-
let aggregation in response to ADP in the presence of prostaglandin
E1. Tubes containing PPACK-anticoagulated whole blood were
inserted into the VerifyNow PRUTest cartridge within the VerifyNow
analyser, according to the manufacturer’s instructions, and P2Y12
reaction units (PRU) were recorded.
Platelet-rich plasma (PRP) was prepared by centrifugation of PPACK-
anticoagulated blood at 200 g for 7 min, then platelet-poor plasma was
prepared by centrifugation at 1800 g for 10 min for use as calibration
only. Light transmittance aggregometry (LTA) was performed pre-dose
and 30 min, 1, 2, and 8 h post-dose using the available aggregometer at
each site (see Supplementary material online) with aggregation recorded
as maximum percentage platelet aggregation over 6 min after addition of
ADP 20lmol/L as agonist.13
All laboratory consumables for platelet function studies were provided
to sites by CirQuest Labs (Memphis, TN, USA).
Pharmacokinetic assessments
Plasma concentrations of selatogrel were measured by Idorsia
Pharmaceuticals Ltd (Allschwil, Switzerland) using a validated high-
performance liquid chromatography-tandem mass spectrometry assay, as
previously described.14
Safety assessments
Adverse events (AEs) were recorded up to 1 month. Treatment-
emergent AEs were defined as occurring within 48 h of administration of
study medication. All bleeding events were recorded, regardless of sever-
ity. Safety assessments included treatment-emergent changes in heart
rate, blood pressure, electrocardiographic parameters, and clinical la-
boratory measurements (including full blood count, electrolytes, liver and
renal function, and urate).
A Safety Event Committee consisting of two independent clinical
experts reviewed unblinded safety data independently from the sponsor
during the study.
Statistical analyses
Data are presented on all randomized patients who were administered
study treatment. Continuous variables are presented as mean and stand-
ard deviation (SD), mean and 95% confidence interval (CI), or median
and interquartile range, as indicated, and categorical variables as number
of patients and percentage.
The primary PD endpoint was the proportion of patients responding
to selatogrel, with ‘responders’ pre-defined as having PRU <100 at 30
min after injection and lasting >_3 h. This PRU threshold was chosen in
order to reflect the typical levels of platelet reactivity achieved by ticagre-
lor or prasugrel loading in ACS patients.13,15,16
The study aimed at assessing the efficacy of each selatogrel dose vs.
placebo using a hierarchical two-step approach. A P-value significance
level was set to 0.025 for each of the two steps, based on an overall
Type-I error rate of 0.05 adjusted for multiple comparisons using a
Bonferroni approach (two comparisons within each sequential step). For
the first step, the proportion of responders for each of the two doses of
selatogrel was compared to placebo (assuming 50% responders with pla-
cebo). In step two, for doses superior to placebo it was tested if the pro-
portion of responders was >70%. Assuming 10% drop-out or non-
evaluable data, each arm was intended to include at least 108 patients to
achieve 90% power.
Platelet aggregation was compared using a mixed-effects model with
treatment group (selatogrel 8 mg, selatogrel 16 mg, placebo), injection
site (abdomen, thigh), PRU level at baseline (stratification levels), age
(continuous), and sex (male and female) as fixed factors. The model also
included (treatment*injection site) as an interaction term to assess
Figure 1 Patient screening and randomization schedule.
3134 R.F. Storey et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article/41/33/3132/5625727 by guest on 10 N
ovem
ber 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
consistency of treatment effect across injection sites. Additional explora-
tory comparisons of PD data were performed at each time point, com-
paring each selatogrel dose with placebo using the Student’s t-test, and P
values are presented descriptively.
Plasma selatogrel concentrations are presented as arithmetic mean
and SD. Peak plasma concentrations (Cmax) and the time to Cmax (Tmax)
were estimated using non-compartmental methods.
Results
Study population
The study was conducted between January and September 2018. A
total of 346 patients with CCS were randomized, of whom 345
received study medication [selatogrel 8 mg (n = 114), selatogrel
16 mg (n = 115), or placebo (n = 116)]: one patient in the selatogrel
8-mg group did not proceed to treatment with study medication and
was excluded from the presented analyses (Figure 1). All treated
patients completed the study except for one patient who died before
the 1-month follow-up. Demographics, baseline characteristics, and
concomitant antiplatelet medications were well balanced across the
treatment groups (Table 1).
Pharmacodynamic responses
One hundred and two out of 114 patients (89%; 95% CI 82–94%)
were responders to selatogrel 8 mg, 103 out of 115 patients (90%;
95% CI 82–94%) were responders to selatogrel 16 mg, and 18 out of
116 patients (16%; 95% CI 9–23%) were responders to placebo
(P < 0.0001 for each selatogrel dose vs. placebo). There was no statis-
tically significant interaction for injection site, age, or sex on PRU
change from baseline (repeated-measures mixed model). Response
by subgroup is presented in the Supplementary material online, Figure
S1. At baseline, mean PRU levels were similar across all groups (sela-
togrel 8 mg: 156 ± 71; selatogrel 16 mg: 156 ± 77; placebo: 155 ± 73).
At 15 min post-dose, PRU values (mean ± SD) were 10 ± 25 with
selatogrel 8 mg, 4 ± 10 with selatogrel 16 mg, and 163 ± 73 with pla-
cebo. PRU levels were maintained below 100 for up to 8 h for both
selatogrel doses, returning to pre-dose or near pre-dose levels by
24 h post-dose [(24 h vs. pre-dose PRU level) selatogrel 8 mg:
144 ± 74 vs. 156 ± 72; selatogrel 16 mg: 129± 66 vs. 157± 76; pla-
cebo: 153± 74 vs. 153 ± 73](Figure 2A).
Absolute PRU values for each treatment were not different be-
tween injection sites (Supplementary material online, Figure S2).
LTA showed similar findings to VerifyNow, with rapid onset of
antiplatelet effect (Figure 2B).
A consistent PD profile for both doses of selatogrel was noted in
patients regardless of baseline oral P2Y12 inhibitor therapy (Figure 3).
Pharmacokinetics
Selatogrel was rapidly absorbed as indicated by the achievement of
Cmax shortly after the 30-min time point (tmax, mean ± SD, selatogrel
8 mg: 40 ± 14 min; selatogrel 16 mg: 44± 18 min) (Figure 4). The Cmax
(mean ± SD) following administration of selatogrel 8 and 16 mg was
316 ± 117 and 513± 171 ng/mL, respectively. Plasma selatogrel con-
centrations declined steadily over the 24-h post-dose period with
estimated mean ± SD levels of 0.4 ± 0.6 and 2.1 ± 0.9 ng/mL at 24 h
following 8 and 16 mg doses, respectively. There was no difference in
plasma selatogrel concentration according to the site of injection, i.e.
thigh or abdomen (Supplementary material online, Figure S3).
Adverse events
Bleeding events occurred in 9.6% (95% CI: 4.9–16.6%) and 4.3% (95%
CI: 1.4–9.9%) with selatogrel 8 and 16 mg, respectively, vs. 6.9% (95%
CI: 3.0–13.1%) with placebo. Transient dyspnoea (mild in all but one
patient who had moderate dyspnoea on selatogrel 16 mg) occurred
in 5.3% (95% CI: 2.0–11.1%) and 8.7% (95% CI: 4.3–15.4%) with sela-
togrel 8 and 16 mg, respectively, vs. none with placebo; median (min–
max) duration of dyspnoea was 2.4 (0.1–8.4) h and 0.8 (0.0–22.1) h
for the 8 and 16 mg selatogrel doses, respectively. Dizziness occurred
in 4.4% (95% CI: 1.4–9.9%) and 3.5% (95% CI: 1.0–8.7%) vs. 0.9%
(95% CI: 0.02–4.7%), respectively, without significant haemodynamic
or electrocardiographic changes (Table 2).
There were no treatment-emergent deaths or other serious AEs.
One patient in the selatogrel 8 mg group died 17 days after selatogrel
administration as a result of cardiac arrest and this was not consid-
ered by the investigator to be related to study drug administration.
No marked treatment-emergent differences in heart rate, blood
pressure or electrocardiographic findings, including bradycardia,
atrioventricular block, and QT interval, were observed with either
dose of selatogrel, compared with placebo (Supplementary material
online, Table S1 and Figure S4). There were no notable treatment-
related changes in biochemistry or haematology parameters
(Supplementary material online, Table S2).
Discussion
The present study is the first to characterize the antiplatelet effect of
selatogrel (8 and 16 mg) in CCS patients. Both doses of selatogrel
produced similar PD and PK profiles, with no difference between
thigh and abdomen injection sites. Selatogrel was rapidly absorbed
following single-dose s.c. administration, translating into a fast onset
of a high level of platelet inhibition that was maintained for >_8 h and
reversible within 24 h. A high level of platelet inhibition was rapidly
achieved in patients who were not receiving an oral P2Y12 inhibitor.
Both doses of selatogrel also rapidly achieved additional platelet in-
hibition in patients established on an oral P2Y12 inhibitor with, as
expected, greater incremental platelet inhibition in patients on clopi-
dogrel compared with prasugrel or ticagrelor (Figure 3B–D). This is
particularly relevant in the case of patients who sustain thrombotic
events in the context of poor PD response to clopidogrel or as a re-
sult of poor adherence to oral therapy.
The potent oral P2Y12 inhibitors ticagrelor and prasugrel have
been shown to have onset of action within 1–2 h in CCS patients.17–
19 However, it was subsequently discovered that their onset of action
is more variable and often delayed by several hours in patients with
AMI.20,21 Part of this phenomenon has been attributed to the use of
parenteral opiates, which delay gastric emptying and, therefore, may
slow the onset of action of orally administered drugs, including P2Y12
inhibitors.19,22 Based on data obtained from CCS patients, the fast
onset of platelet aggregation inhibition within 15 min of single-dose
s.c. selatogrel injection makes it a potential candidate to address the
need for reliably rapid platelet inhibition in patients with AMI, which
is not provided by current oral P2Y12 inhibitors. This hypothesis was
Selatogrel, a subcutaneous P2Y12 receptor antagonists 3135
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tested, as part of the development programme of selatogrel, in a
complementary study investigating PK and PD properties of selatog-
rel in AMI patients (ClinicalTrials.gov NCT03487445).
The reported treatment-emergent AEs suggest that selatogrel is
safe and well tolerated in this patient population. An excess of
dyspnoea AEs was noted with both doses of selatogrel compared
with placebo, with all the events being mild apart from one that was
moderate in severity. This is similar to findings with other reversibly-
binding P2Y12 inhibitors, including ticagrelor,
23,24 elinogrel,25 and
cangrelor,26 as compared with the irreversible inhibitor clopidogrel.27
However, the aetiology of dyspnoea following P2Y12 inhibition is not
yet fully understood. Non-dyspnoea AEs that occurred in numerically
more selatogrel-treated patients require further assessment in a
larger trial to further explore the AE profile. In particular, bleeding
events need further assessment since such events in this study were
mostly trivial, related to venepuncture and s.c. injection of study drug.
A limitation of this study was that patients were stable and it is
possible that some patients with acute conditions have reduced skin
....................................................................................................................................................................................................................
Table 1 Patient characteristics
Selatogrel 8 mg
(n 5 114)
Selatogrel 16 mg
(n 5 115)
Placebo
(n 5 116)
Age, years, mean (SD) 64.8 (9.4) 65.2 (8.5) 64.9 (9.1)
Female sex, n (%) 20 (18) 26 (23) 23 (20)
Body weight, kg, median (IQR) 87 (76–102) 85 (76–99) 90 (82–101)
Body mass index, mean (SD) 29 (5) 29 (6) 31 (5)
Race, n, (%)
White 97 (85) 96 (83) 103 (89)
Black 10 (9) 13 (11) 9 (8)
Asian 7 (6) 6 (5) 4 (3)
Prior medical history, n (%)
PCI 89 (78) 94 (82) 100 (86)
CABG surgery 36 (32) 19 (17) 23 (20)
Myocardial infarction 73 (64) 68 (59) 78 (67)
Stroke 4 (4) 5 (4) 3 (3)
Transient ischaemic attack 3 (3) 2 (2) 1 (1)
Peripheral vascular surgery 3 (3) 3 (3) 4 (3)
Congestive cardiac failure 8 (7) 7 (6) 4 (3)
Diabetes mellitus 34 (30) 35 (30) 39 (34)
Hypertension 88 (77) 85 (74) 78 (67)
Dyslipidaemia 80 (70) 81 (70) 77 (66)
Peripheral arterial disease 5 (4) 2 (2) 3 (3)
Chronic kidney disease 9 (8) 5 (4) 4 (3)
Concomitant antiplatelet medication, n (%)
Aspirina 109 (96) 111 (97) 114 (98)
Any oral P2Y12 inhibitor 35 (31) 41 (36) 43 (37)
Clopidogrel 25 (22) 23 (20) 30 (26)
Ticagrelor 7 (6) 11 (10) 10 (9)
Prasugrel 3 (3) 7 (6) 3 (3)
No aspirina or P2Y12 inhibitor 2 (2) 0 (0) 0 (0)
Aspirina þ clopidogrel 22 (19) 19 (17) 28 (24)
Aspirina þ ticagrelor 7 (6) 11 (10) 10 (9)
Aspirina þ prasugrel 3 (3) 7 (6) 3 (3)
Other medication, n (%)
Proton-pump inhibitors 41 (36) 42 (37) 49 (42)
Nitrates 41 (36) 42 (37) 50 (43)
Beta-blockers 75 (66) 80 (70) 76 (66)
Statins 106 (93) 108 (94) 104 (90)
ACE inhibitors 54 (47) 63 (55) 58 (50)
Angiotensin receptor blockers 27 (24) 20 (17) 26 (22)
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; IQR, interquartile range; PCI, percutaneous coronary intervention.
aIncluding carbasalate calcium.
3136 R.F. Storey et al.
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Figure 2 Effects of selatogrel on adenosine diphosphate-induced platelet aggregation. (A) P2Y12 reaction units assessed by VerifyNow PRUTest
assay and (B) maximum platelet aggregation response to adenosine diphosphate 20lmol/L determined by LTA at the indicated time points before
and after administration of subcutaneous selatogrel 8 mg (n = 114), selatogrel 16 mg (n = 115), or placebo (n = 116). Data are mean and error bars in-
dicate 95% confidence interval. Exploratory P values comparing each dose of selatogrel with placebo at each time point are derived from the
Student’s t-test.
Figure 3 Effects of selatogrel on platelet reactivity assessed as P2Y12 reaction units by VerifyNow PRUTest assay according to treatment with (A)
no oral P2Y12 inhibitor (n = 30–35 per group), (B) clopidogrel (n = 18–21 per group), (C) prasugrel (n = 3–6 per group), or (D) ticagrelor (n = 7–11
per group). Data are mean and error bars indicate 95% confidence interval. Exploratory P values comparing each dose of selatogrel with placebo at
each time point are derived from the Student’s t-test.
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and organ perfusion that delays the absorption of selatogrel.
Consequently, it is important that the onset of action of s.c. selatogrel
is also assessed in acute conditions, as has been performed in a separ-
ate study in AMI patients (ClinicalTrials.gov NCT03487445). We also
did not assess the transition between selatogrel administration and
loading with oral P2Y12 inhibitors. It is recognized that cangrelor
impedes the binding of clopidogrel and prasugrel active metabolites
to the P2Y12 receptor leading to drug–drug interactions
28 and further
work is required to identify optimal strategies for transitioning from
selatogrel to oral therapy. A further limitation of this study was the
method of blood sample collection. The potency of selatogrel is
lower in citrated PRP as compared with PRP anticoagulated with a
direct thrombin inhibitor.14 Further investigations (data on file) to
profile the influence of various methods of anticoagulation confirmed
that physiological ionized calcium concentrations are important for
determination of potency of selatogrel. Accordingly, to perform the
platelet aggregation assays, blood was collected with PPACK as anti-
coagulant. PRU levels tend to be slightly lower with blood antico-
agulated with a direct thrombin inhibitor compared to citrate-
anticoagulated blood.11,12 For this reason, any direct comparison
of absolute PRU values obtained in this study with those
published from studies of other P2Y12 inhibitors should be
avoided.
Conclusions
In patients with CCS, selatogrel (8 and 16 mg) was rapidly
absorbed following single-dose s.c. injection resulting in strong in-
hibition of platelet reactivity as early as 15 min that was main-
tained for >_8 h and reversible within 24 h. The PD and PK profiles
characterized in this study suggest s.c. selatogrel may be a promis-
ing treatment in the pre-hospital setting and in clinical scenarios
where early, rapid, potent and reversible platelet inhibition is de-
sirable, such as patients presenting with AMI or undergoing PCI.
Further clinical investigation of selatogrel in these patient popula-
tions is required, and will further inform selection of the optimal
dose for Phase 3 clinical studies.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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